Development
AbbVie Inc.
ABBV
$191.08
-$1.34-0.70%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 2.69% | 0.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.69% | 0.45% | |||
| Cost of Revenue | -33.87% | 53.64% | |||
| Gross Profit | 34.36% | -22.73% | |||
| SG&A Expenses | 8.82% | 3.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.86% | 25.97% | |||
| Operating Income | 83.95% | -48.18% | |||
| Income Before Tax | -37.94% | -25.17% | |||
| Income Tax Expenses | 125.58% | -70.50% | |||
| Earnings from Continuing Operations | -53.73% | -12.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 33.33% | 0.00% | |||
| Net Income | -53.77% | -12.15% | |||
| EBIT | 83.95% | -48.18% | |||
| EBITDA | 40.72% | -33.05% | |||
| EPS Basic | -54.23% | -12.22% | |||
| Normalized Basic EPS | 100.84% | -52.68% | |||
| EPS Diluted | -54.23% | -12.22% | |||
| Normalized Diluted EPS | 101.31% | -52.68% | |||
| Average Basic Shares Outstanding | 0.28% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.00% | |||
| Dividend Per Share | 4.73% | 0.00% | |||
| Payout Ratio | 1.16% | 0.14% | |||